FDA approves cabozantinib to treat rare type of thyroid cancer

Article

FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
Related Content
Strategies for Expanding Revenue Streams in Independent Pharmacy Today and in the Future

Strategies for Expanding Revenue Streams in Independent Pharmacy Today and in the Future

Brian Nowosielski
August 15th 2025
Article
The Evolving Pharmacy Landscape Paving the Way for Non-Traditional Roles

The Evolving Pharmacy Landscape Paving the Way for Non-Traditional Roles

Brian Nowosielski;Ashley Kay Pendrick, PharmD
August 15th 2025
Podcast
Independent Pharmacies Opening, Closing More Than Chain Storefronts

Independent Pharmacies Opening, Closing More Than Chain Storefronts

Brian Nowosielski
August 15th 2025
Article
Scripted for Her: Understanding Grief

Scripted for Her: Understanding Grief

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Lois Hall, MS
August 15th 2025
Podcast
Community Pharmacies Are Safe, Accessible Locations for Adolescent Reproductive Health Care

Community Pharmacies Are Safe, Accessible Locations for Adolescent Reproductive Health Care

Ashley Gallagher
August 15th 2025
Article
Novel Therapy Could Help Patients Keep Weight Off After Stopping GLP-1s

Novel Therapy Could Help Patients Keep Weight Off After Stopping GLP-1s

Killian Meara
August 15th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.